p53-dependent transcriptional repression of c-myc is required for G 1 cell cycle arrest

Molecular and Cellular Biology

Volumn 25, Issue 17, 2005, Pages 7423-7431

  Ho, Jenny S L ^b   Ma, Weili ^b   Mao, Daniel Y L ^b   Benchimol, Samuel ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; MYC PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR SIN3A; TRICHOSTATIN A;

ACETYLATION; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MITOSIS INHIBITION; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION TERMINATION;

ACETYLATION; ANIMALS; BASE SEQUENCE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G1 PHASE; GENE EXPRESSION REGULATION; HISTONES; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23844476499     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.17.7423-7431.2005     Document Type: Article

References (48)

1. Chen, C. R., Y. Kang, P. M. Siegel, and J. Massague. 2002. E2F4/5 and p107 as Smad cofactors linking the TGFβ receptor to c-myc repression. Cell 110:19-32.
2. Chiou, S. K., L. Rao, and E. White. 1994. Bcl-2 blocks p53-dependent apoptosis. Mol. Cell. Biol. 14:2556-2563.
3. Coppola, J. A., and M. D. Cole. 1986. Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. Nature 320:760-763.
4. D'Souza, S., H. Xin, S. Walter, and D. Choubey. 2001. The gene encoding p202, an interferon-inducible negative regulator of the p53 tumor suppressor, is a target of p53-mediated transcriptional repression. J. Biol. Chem. 276:298-305.
5. Eberhardy, S. R., C. A. D'Cunha, and P. J. Farnham. 2000. Direct examination of histone acetylation on Myc target genes using chromatin immunoprecipitation. J. Biol. Chem. 275:33798-33805.
6. L or Bcl-2 is bypassed during lymphomagenesis. Mol. Cell. Biol. 21:5063-5070.
7. el-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kanzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
8. el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
9. Ferreira, R., L. Magnaghi-Jaulin, P. Robin, A. Harel-Bellan, and D. Trouche. 1998. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc. Natl. Acad. Sci. USA 95:10493-10498.
10. Gottifredi, V., O. Karni-Schmidt, S. S. Shieh, and C. Prives. 2001. p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Mol. Cell. Biol. 21:1066-1076.
11. Hermeking, H., J. O. Funk, M. Reichert, J. W. Ellwart, and D. Eick. 1995. Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDH. Oncogene 11:1409-1415.
12. Ho, J., and S. Benchimol. 2003. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ. 10:404-408.
13. Hoffman, W. H., S. Biade, J. T. Zilfou, J. Chen, and M. Murphy. 2002. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277:3247-3257.
14. Hundley, J. E., S. K. Koester, D. A. Troyer, S. G. Hilsenbeck, M. A. Subler, and J. J. Windle. 1997. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol. Cell. Biol. 17:723-731.
15. Hung, L., and V. Kumar. 2004. Specific inhibition of gene expression and transactivation functions of hepatitis B virus X protein and c-myc by small interfering RNAs. FEBS Lett. 560:210-214.
16. Johnson, P., S. Chung, and S. Benchimol. 1993. Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol. Cell. Biol. 13:1456-1463.
17. Jones, J. M., L. Attardi, L. A. Godley, R. Laucirica, D. Medina, T. Jacks, H. E. Varmus, and L. A. Donehower. 1997. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ. 8:829-838.
18. Juin, P., A. O. Hueber, T. Littlewood, and G. Evan. 1999. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 13:1367-1381.
19. Kastan, M. B., Q. Zhan, W. S. el-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597.
20. Larsson, L. G., I. Ivhed, M. Gidlund, U. Pettersson, B. Vennstrom, and K. Nilsson. 1988. Phorbol ester-induced terminal differentiation is inhibited in human U-937 monoblastic cells expressing a v-myc oncogene. Proc. Natl. Acad. Sci. USA 85:2638-2642.
21. Leng, R. P., Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J. M. Parant, G. Lozano, R. Hakem, and S. Benchimol. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112:779-791.
22. Levy, N., E. Yonish-Rouach, M. Oren, and A. Kimchi. 1993. Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperatively with c-myc suppression. Mol. Cell. Biol. 13:7942-7952.
23. Lohr, K., C. Moritz, A. Contente, and M. Dobbelstein. 2003. p21/CDKN1A mediates negative regulation of transcription by p53. J. Biol. Chem. 278: 32507-32516.
24. Lotem, J., and L. Sachs. 2002. Epigenetics wins over genetics: induction of differentiation in tumor cells. Semin. Cancer Biol. 12:339-346.
25. Luo, Q., J. Li, B. Cenkci, and L. Kretzner. 2004. Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product. Oncogene 23:1088-1097.
26. Marhin, W. W., S. Chen, L. M. Facchini, A. J. Fornace, Jr., and L. Z. Penn. 1997. Myc represses the growth arrest gene gadd45. Oncogene 14:2825-2834.
27. Waf1/Cip1-deficient mice. Cancer Res. 61: 6234-6238.
28. Miner, J. H., and B. J. Wold. 1991. c-myc inhibition of MyoD and myogenin-initiated myogenic differentiation. Mol. Cell. Biol. 11:2842-2851.
29. Mirza, A., M. McGuirk, T. N. Hockenberry, Q. Wu, H. Ashar, S. Black, S. F. Wen, L. Wang, P. Kirschmeier, W. R. Bishop, L. L. Nielsen, C. B. Pickett, and S. Liu. 2002. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613-2622.
30. WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ. 10:223-230.
31. Murphy, M., J. Ahn, K. K. Walker, W. H. Hoffman, R. M. Evans, A. J. Levine, and D. L. George. 1999. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13:2490-2501.
32. Murphy, M., A. Hinman, and A. J. Levine. 1996. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 10:2971-2980.
33. Pelengaris, S., M. Khan, and G. Evan. 2002. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2:764-776.
34. Ragimov, N., A. Krauskopf, N. Navot, V. Rotter, M. Oren, and Y. Aloni. 1993. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8:1183-1193.
35. Rayman, J. B., Y. Takahashi, V. B. Indjeian, J. H. Dannenberg, S. Catchpole, R. J. Watson, H. te Riele, and B. D. Dynlacht. 2002. E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev. 16:933-947.
36. Schmitt, C. A., J. S. Fridman, M. Yang, E. Baranov, R. M. Hoffman, and S. W. Lowe. 2002. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289-298.
37. Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419:729-734.
38. Shats, I., M. Milyavsky, X. Tang, P. Stambolsky, N. Erez, R. Brosh, I. Kogan, I. Braunstein, M. Tzukerman, D. Ginsberg, and V. Rotter. 2004. p53-dependent downregulation of telomerase is mediated by p21/waf1. J. Biol. Chem. 65:4530-4543.
39. Shaulian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12:5581-5592.
40. Singh, B., P. G. Reddy, A. Goberdhan, C. Walsh, S. Dao, I. Ngai, T. C. Chou, O. C. P., A. J. Levine, P. H. Rao, and A. Stoffel. 2002. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 16:984-993.
41. Soucie, E. L., M. G. Annis, J. Sedivy, J. Filmus, B. Leber, D. W. Andrews, and L. Z. Penn. 2001. Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol. Cell. Biol. 21:4725-4736.
42. St. Clair, S., L. Giono, S. Varmeh-Ziaie, L. Resnick-Silverman, W. J. Liu, A. Padi, J. Dastidar, A. DaCosta, M. Mattia, and J. J. Manfredi. 2004. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol. Cell 16:725-736.
43. Sutcliffe, T., L. Fu, J. Abraham, H. Vaziri, and S. Benchimol. 1998. A functional wild-type p53 gene is expressed in human acute myeloid leukemia cell lines. Blood 92:2977-2979.
44. Symonds, H., L. Krall, L. Remington, M. Saenz-Robles, S. Lowe, T. Jacks, and T. Van Dyke. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711.
45. Thompson, C. B., E. H. Humphries, L. M. Carlson, C. L. Chen, and P. E. Neiman. 1987. The effect of alterations in myc gene expression on B cell development in the bursa of Fabricius. Cell 51:371-381.
46. Vafa, O., M. Wade, S. Kern, M. Beeche, T. K. Pandita, G. M. Hampton, and G. M. Wahl. 2002. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 9:1031-1044.
47. Vaziri, H., and S. Benchimol. 1998. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8:279-282.
48. Wang, Y., L. Szekely, I. Okan, G. Klein, and K. G. Wiman. 1993. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8:3427-3431.